AML1-ETO needs a partner: New insights into the pathogenesis of t(8;21) leukemia

Cell Cycle

Volumn 4, Issue 12, 2005, Pages 1716-1718

  Kuchenbauer, F ^a,b   Feuring Buske, M ^a,b   Buske, C ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

AML1 ETO; CBF leukemia; FLT3 LM; KIT mutation; RTK inhibitor

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER INCIDENCE; CHROMOSOME ABERRATION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LEUKEMIA; MUTATION; NONHUMAN; PATHOGENESIS; SHORT SURVEY;

EID: 29244466856     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.12.2256     Document Type: Short Survey

References (18)

1. Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16:109-112.
2. Rowley JD. Molecular genetics in acute leukemia. Leukemia 2000; 14:513-517.
3. Ferrara F, Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: A distinct biological and clinical entity. Haematologica 2002; 87:306-19.
4. Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L. Prognostic impact of C-Kit mutations in core binding factor-leukemia. Blood 2004; 103:2013.
5. Boissel N, Leroy H, De Botton S, et al. Incidence and prognosis of RTKs and RAS mutations in CBF AML. A Retrospective Study of French Adult ALFA and Pediatric LAME Trials. Blood 2004; 103:2022.
6. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1:63-74.
7. Schwieger M, Lohler J, Friel J, Scheller M, Horak I, Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 2002; 196:1227-40.
8. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115:2159-68.
9. Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. Deletion of an AML1-ETO C-terminal NcoR/ SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 2004; 101:17186-91.
10. Era T, Asou N, Kunisada T, Yamasaki H, Asou H, Kamada N, Nishikawa S, Yamaguchi K, Takatsuki K. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells. Genes Chromosomes Cancer 1995; 13:25-33.
11. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, Kamada N, Ohki M. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82:1270-6.
12. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddemann W. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59-66.
13. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278:1059-64.
14. Gilliland DG. Molecular genetics of human leukemias: New insights into therapy. Semin Hematol 2002; 39:6-11.
15. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Mutations in KIT and RAS are frequent events in pediatric corebinding factor acute myeloid leukemia. Leukemia 2005; 19:1536-42.
16. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102:1104-9.
17. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106:1154-63.
18. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-87.